➼ Basic Information
Deoxycholic Acid/Kybella® is the world's first topical lipolysis drug approved by the US Food and Drug Administration (FDA) on April 29, 2015. The drug is developed, produced and marketed by Kythera Biopharmaceuticals, a subsidiary of Allergan.
Deoxycholic acid injection is approved for the treatment and improvement of bulges or plump (double chin) in adults with moderate to severe axillary fat. Kybella® is a subcutaneous injection containing 10 mg/mL deoxycholic acid, 2 mL per vial. The recommended dose is 0.2 mL of deoxycholic acid injection per subcutaneous injection. In the planned injection area, each interval is 1 cm, and no more than 50 injection points or 10 mL of deoxycholic acid injection per administration. A maximum of 6 single treatments can be performed at intervals of not less than 1 month.
➾ Structural formula：
➾ Mechanism
Deoxycholic acid is a free bile acid present in bile. It has strong surface activity and can destroy and dissolve cell membranes, so that a small amount of local subcutaneous fat dissolution is reduced.
⟹ Synthetic route：
⟹ Research key data
⟹ Research and marketing drugs with the same target：
